Cell-Based Assays: Technologies and Global Markets
Report Highlights
The global cell-based assays market should reach $47.3 billion by 2027 from $29.2 billion in 2022 at a compound annual growth rate (CAGR) of 10.2% for the forecast period of 2022 to 2027.
Report Includes
- 63 tables
- An up-to-date review of the global markets for cell-based assays and related technologies
- Analyses of the global market trends, with historic sales data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future potential in the market for cell-based assays, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size for cell-based assays, revenue forecast, and corresponding market share analysis based on product, type/application, end user and geographic region
- Market assessment of the cell-based assays available and currently being used, new developments, spending trends, and revenue prospects for cell-based assays in the pharmaceutical industry
- Coverage of major issues involved in the research and development (R&D) of more effective cell-based approaches for drug discovery
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
- Competitive analysis of the market for cell-based assays and updated information on the mergers, acquisitions, collaborations and recent developments during the 2020-2022 period
- Descriptive company profiles of the leading global players, including Becton, Dickinson & Company, Charles River Laboratories, General Electric Healthcare, Merck KGaA and Thermo Fisher Scientific Inc.
Report Scope
This report is an update of an earlier report of the same title. This report offers a comprehensive analysis of the global cell-based assays market. Segmentation is based on product, type/application and end user. Based on type/application, the market is segmented as drug discovery for validating drug targets/lead profiling assays, absorption, distribution, metabolism, and excretion (ADME) toxicity assays and basic research. The regional markets covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
The report provides a detailed overview and analysis of the present and future global market for cell-based assay techniques. The report analyzes in detail currently available cell-based assays and their markets. Industry growth drivers, restraints and opportunities are also discussed in detail. The report also provides information on competitive landscape, elaborative company profiles and the impact of COVID-19 on the market.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2021 |
| Forecast period considered | 2022–2027 |
| Base year market size | $26.5 billion |
| Market size forecast | $47.3 billion |
| Growth rate | CAGR of 10.2% from 2022 to 2027 |
| Units considered | $ Millions |
| Segments covered | Application, Segment, End User, Region |
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Countries covered | U.K., Germany, France, Italy, Spain, Rest of Europe, China, Japan, India, Rest of Asia-Pacific, U.S., Canada |
| Key Market Drivers |
|
| Companies studied |
|
Report Highlights
The global market for cell-based assays should grow from $20.1 billion in 2018 to $32.7 billion by 2023 at a compound annual growth rate (CAGR) of 10.2% from 2018 through 2023.
Report Includes
- 23 data tables and 48 additional tables
- Detailed overview of the global market for cell-based assays within the industry
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Details of important assays, technologies and the latest developments and outlines market shares by assay type and company, with a special emphasis on the U.S. market
- Regional dynamics of cell-based assays covering North America, Europe and other emerging economies
- Examination of the cell-based assays available and currently being used, new developments, spending trends, and revenue prospects for cell-based assays in the pharmaceutical industry
- Discussion of current issues and trends affecting the industry, as well as costs and factors that have an impact on demand
- Coverage of major issues involved in the research and development (R&D) of more effective cell-based approaches for drug discovery
- Company profiles of major players in the industry including Beckman Coulter, DiscoverX, PerkinElmer, Life Technologies and Promega Corp.
Report Highlights
The global market for cell-based assays reached $15.2 billion in 2015. This market is expected to increase from $17.1 billion in 2016 to nearly $28.4 billion in 2021 at a compound annual growth rate (CAGR) of 10.6% for 2016-2021.
Report Includes
- An overview of the global markets and related technologies for cell-based assays.
- Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examinations of major issues involved in the research and development (R&D) of more effective cell-based approaches, for drug discovery and absorption, distribution, metabolism, and excretion (ADME)/ toxicity assays in development and in use.
- The current market status of cell-based assays in terms of strengths, weaknesses, opportunities and threats facing various assays and developments already on the market.
- Discussion of current issues and trends affecting the industry, and costs and other factors influencing demand.
- Coverage of new technologies, trends, alliances, and mergers.
- Profiles of major players in the industry.
Report Highlights
BCC Research estimates that the global market for cell-based assays will increase at a compound annual growth rate (CAGR) of 12.4% over the next five years to reach $15.2 billion in 2015 and $21.6 billion by 2018 from $12.1 billion in 2013.
Report Includes
- An overview of the global market for cell-based assays available and currently used.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examinations of major issues involved in the research and development (R&D) of more effective cell-based approaches, for drug discovery, and absorption, distribution, metabolism, and excretion (ADME)/ toxicity assays in development and in use.
- Discussion of current issues and trends affecting the industry, and costs and other factors influencing demand.
- Coverage of new technologies, trends, alliances, and mergers.
Report Highlights
Cell biology is currently the biggest revenue contributor to the life-science tools industry, accounting for approximately 30% of total sales. It is expected to grow to a $15 billion market by 2015, increasing at a compound annual growth rate (CAGR) of 12.3% from its 2010 value of $8.5 billion.